Clinical trials with etanidazole (SR-2508) by the radiation therapy oncology group (RTOG)

doi:10.1016/0167-8140(91)90200-Z

Radiotherapy and Oncology

Volume 20, Supplement, 1991, Pages 129-135

https://doi.org/10.1016/0167-8140(91)90200-Z Get rights and content

Abstract

Following the completion of a phase I study of etanidazole (SR 2508), a new hypoxic cell sensitizer, the RTOG, began a phase II/III trial. The objectives of the study were to determine the toxicity and efficacy of SR 2508, combined with conventional radiotherapy for the management of unresectable stage III and IV head and neck squamous carcinomas.

During the first step (or the Phase II portion) of the study, 33 patients received radiotherapy plus SR 2508 (RT + SR 2508). The incidence of drug toxicities was modest; including 24% grade I peripheral neuropathy (PN), 6% grade II PN, 27% grade I or II nausea and vomiting, 9% allergy and 15% reversible neutropenia. Because observed toxicities were deemed acceptable, the second step (or phase III portion) was then activated. Patients were randomized to receive either RT or RT + SR 2508. As of November 20, 1989, a total of 242 patients have been entered onto the Phase III portion of the study. One hundred twenty-two patients were randomized to the RT + SR 2508 arm and 120 patients were randomized to the RT alone arm. The analyses presented in this report are based on data available [11]. The incidence of drug toxicities has been low, with 18% grade I or II PN, 26% nausea and vomiting (including one grade III), 14% allergy (including one grade III) and 13% reversible neutropenia. Blood samples were obtained at 0, 15 and 60 min, and 2, 4, and 20–24 hours following the administration of the first or second dose of SR 2508, for the measurement of serum drug concentration, and determination of the area under the curve (AUC). The average single drug dose AUC for 110 patients with data presently available, was 2.55 ± 0.86 mM-hr.

The observed incidences of radiotherapy related toxicities in RT + SR 2508 group were not different from those in RT alone group.

Preliminary analysis of the treatment results, showed that the 33 patients from the phase II part had achieved an initial complete response rate of 58%. Considering the fact that 61% of the patients had T4 and 49% had N3, this result is encouraging.

With an accrual rate of 15 cases per month, this study will meet its patient accrual goal in 1990, and the results concerning the SR 2508 efficacy will be available after another year of follow up.

References (12)

C.N. Coleman et al.
Phase I trial of the hypoxic cell radiosensitizer SR 2508: The results of the five to six week drug schedule
Int. J. Radiat. Oncol. Biol. Phys.
(1986)
C.N. Coleman et al.
Initial report of the phase I trial of the hypoxic cell radiosensitizer SR 2508
Int. J. Radiat. Oncol. Biol. Phys.
(1984)
C.N. Coleman et al.
Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile
Cancer Res.
(1987)
J.T. Fazekas et al.
The value of adjuvant misonidazole in the definitive irradiation of advanced head and neck squamous cancer: An RTOG pilot study (No. 78-02)
Int. J. Radiat. Oncol. Biol. Phys.
(1981)
J.T. Fazekas et al.
Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III–IV squamous cancers of the head and neck
Int. J. Radiat. Oncol. Biol. Phys.
(1987)
J.M. Henk et al.
Radiotherapy and hyperbaric oxygen in head and neck cancer: Final report of the first clinical trial
Lancet
(1977)

There are more references available in the full text version of this article.

Cited by (18)

Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs
2019, Clinical Oncology
Citation Excerpt :
A variety of treatment regimens were explored to maximise sensitisation while limiting neurotoxicity, thus making interpretation of results challenging [26,46]. Designing more polar analogues with increased systemic clearance to minimise neurotoxicity was only partially successful with the identification of etanidazole [53–55]. Etanidazole displayed excellent activity in tumour models [53], but failed to provide benefit in head and neck cancer [56,57] and in prostate cancer [58].
The role of hypoxia in radiation resistance is well established and many approaches to overcome hypoxia in tumours have been explored, with variable success. Two small molecule strategies for targeting hypoxia have dominated preclinical and clinical efforts. One approach has been the use of electron-affinic nitroheterocycles as oxygen-mimetic sensitisers. These agents are best exemplified by the 5-nitroimidazole nimorazole, which has limited use in conjunction with radiotherapy in head and neck squamous cell carcinoma. The second approach seeks to leverage tumour hypoxia as a tumour-specific address for hypoxia-activated prodrugs. These prodrugs are selectively activated by reductases under hypoxia to release cytotoxins, which in some instances may diffuse to kill surrounding oxic tumour tissue. A number of these hypoxia-activated prodrugs have been examined in clinical trial and the merits and shortcomings of recent examples are discussed. There has been an evolution from delivering DNA-interactive cytotoxins to molecularly targeted agents. Efforts to implement these strategies clinically continue today, but success has been elusive. Several issues have been identified that compromised these clinical campaigns. A failure to consider the extravascular transport and the micropharmacokinetic properties of the prodrugs has reduced efficacy. One key element for these ‘targeted’ approaches is the need to co-develop biomarkers to identify appropriate patients. Hypoxia-activated prodrugs require biomarkers for hypoxia, but also for appropriate activating reductases in tumours, as well as markers of intrinsic sensitivity to the released drug. The field is still evolving and changes in radiation delivery and the impact of immune-oncology will provide fertile ground for future innovation.
Chemical Modifiers of Radiation Response
2010, Leibel and Phillips Textbook of Radiation Oncology, Third Edition
New Developments in Radiation Therapy for Head and Neck Cancer: Intensity-Modulated Radiation Therapy and Hypoxia Targeting
2008, Seminars in Oncology
Citation Excerpt :
A widely investigated hypoxia targeted strategy is to use electron-affinic drugs (nitroimidazoles) to sensitize tumors to radiation; xenograft studies showed significant radiosensitization with nitroimidazole compounds in tumors without enhancing normal tissue toxicity.92,93 For two decades, nitroimidazole compounds were extensively studied by the RTOG and the DAHANCA group in HNC as an adjunct to RT, with mixed results.94-98 Most trials reported disappointing outcomes except for one large study.
Intensity-modulated radiation therapy (IMRT) has revolutionized radiation treatment for head and neck cancers (HNCs). When compared to the traditional techniques, IMRT has the unique ability to minimize the dose delivered to normal tissues without compromising tumor coverage. As a result, side effects from high-dose radiation have decreased and patient quality of life has improved. In addition to toxicity reduction, excellent clinical outcomes have been reported for IMRT. The first part of this review will focus on clinical results of IMRT for HNC. Tumor hypoxia, or the condition of low oxygen, is a key factor for tumor progression and treatment resistance. Hypoxia develops in solid tumors due to aberrant blood vessel formation, fluctuation in blood flow, and increasing oxygen demands for tumor growth. Because hypoxic tumor cells are more resistant to ionizing radiation, hypoxia has been a focus of clinical research in radiation therapy for half a decade. Interest for targeting tumor hypoxia has waxed and waned as promising treatments emerged from the laboratory, only to fail in the clinics. However, with the development of new technologies, the prospect of targeting tumor hypoxia is more tangible. The second half of the review will focus on approaches for assessing tumor hypoxia and on the strategies for targeting this important microenvironmental factor in HNC.
A phase I-B trial of the radiosensitizer: Etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02)
2008, Radiotherapy and Oncology
Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): Radiosensitization efficiency and toxicity
1995, International Journal of Radiation Oncology, Biology, Physics
Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas
1995, International Journal of Radiation Oncology, Biology, Physics

View all citing articles on Scopus

View full text

Clinical trials with etanidazole (SR-2508) by the radiation therapy oncology group (RTOG)

Abstract

Phase I trial of the hypoxic cell radiosensitizer SR 2508: The results of the five to six week drug schedule

Int. J. Radiat. Oncol. Biol. Phys.

Initial report of the phase I trial of the hypoxic cell radiosensitizer SR 2508

Int. J. Radiat. Oncol. Biol. Phys.

Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile

Cancer Res.

The value of adjuvant misonidazole in the definitive irradiation of advanced head and neck squamous cancer: An RTOG pilot study (No. 78-02)

Int. J. Radiat. Oncol. Biol. Phys.

Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III–IV squamous cancers of the head and neck

Int. J. Radiat. Oncol. Biol. Phys.

Radiotherapy and hyperbaric oxygen in head and neck cancer: Final report of the first clinical trial

Lancet